Guidance around complete revascularization and intracoronary imaging is strengthened, and Impella gets a recommendation.

The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

Clyde Yancy talks to Sharonne Hayes and Robert Harrington about the barriers that have historically hindered diagnosing heart ...

Clyde Yancy, Suzanne Baron, and Bruce Rutkin discuss ways to address the undertreatment of CVD in women at the patient, provider, structural, and societal levels.

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

There’s no scientific evidence to support anecdotal claims—on social media or elsewhere—of a bump, Jonathan Drezner says.

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.

A patient who, despite risk factors or comorbidities, can get on a treadmill faces low mortality risk. But the reverse is ...

This month: smelling skills predict stroke risk, insights from LGBTQ+ clinicians, BP screening in public spaces, and more.

The multisociety collaboration moves the focus from procedures to a continuum of care from diagnosis to any treatment ...